Dean B. Evans

发表

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole

G. Hampton, J. Dixon, W. Miller, 2007, Pharmacogenetics and genomics.

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Jingqin Luo, Mitch Dowsett, Matthew J. Ellis, 2008, Journal of the National Cancer Institute.

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

J. Olson, M. Ellis, K. Hunt, 2009, Breast Cancer Research and Treatment.

A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.

Dean B. Evans, A. Bhatnagar, Jonathan R. Green, 2006, Bone.

Increase in response rate by prolonged treatment with neoadjuvant letrozole

David Cameron, G. Kerr, D. Cameron, 2008, Breast Cancer Research and Treatment.

Synergistic activity of letrozole and sorafenib on breast cancer cells

S. Fox, M. Dowsett, A. Harris, 2010, Breast Cancer Research and Treatment.

Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer

Shiuan Chen, H. Lane, T. O'reilly, 2005, Clinical Cancer Research.

DCIS and aromatase inhibitors

J. Dixon, D. Faratian, Jeremy S. Thomas, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Letrozole sensitizes breast cancer cells to ionizing radiation

P. Martineau, G. Romieu, P. Pujol, 2004, Breast Cancer Research.

The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression

Shiuan Chen, Dean B. Evans, Jingjing Ye, 2010, Proceedings of the National Academy of Sciences.

Epitope Characterization of an Aromatase Monoclonal Antibody Suitable for the Assessment of Intratumoral Aromatase Activity

Yate-Ching Yuan, H. Sasano, Shiuan Chen, 2009, PloS one.

B. Rasmussen, H. Mouridsen, H. Sasano, 2022 .

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

T. Sing, W. Miller, J. Dixon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer.

Takashi Suzuki, H. Sasano, Y. Miki, 2010, Human pathology.

Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer

W. Carney, P. Hamer, L. Demers, 2006, Cancer.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

M. Ellis, M. Dowsett, Y. Tao, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intratumoral Estrogens and Estrogen Receptors in Human Non–Small Cell Lung Carcinoma

Takashi Suzuki, H. Sasano, Y. Miki, 2008, Clinical Cancer Research.

Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

T. Aas, P. Lønning, J. Geisler, 2008, Clinical Cancer Research.

De novo synthesis of estrogen in pregnant uterus is critical for stromal decidualization and angiogenesis

Amrita Das, Dean B. Evans, Srinivasa R. Mantena, 2009, Proceedings of the National Academy of Sciences.

Clinical Cancer esearch cer Therapy : Preclinical logical Evidence for Dual Antiangiogenic-Antiaromatase R ivity of the VEGFR Inhibitor PTK 787 / ZK 222584 In vivo

R. A’Hern, Lesley-Ann Martin, A. Banerjee, 2010 .

Actions of calcipotriol (MC 903), a novel vitamin D3 analog, on human bone‐derived cells: Comparison with 1,25‐dihydroxyvitamin D3

J. Kanis, L. Binderup, Dean B. Evans, 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancer

W. Carney, P. Hamer, L. Demers, 2007, Cancer.

Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.

R. Tekmal, N. Kirma, L. Flowers, 2005, Cancer research.

Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.

W. Carney, P. Hamer, L. Demers, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.

S. Hayashi, Dean B. Evans, Y. Yamaguchi, 2011, Oncology reports.

Aromatase, Cyclooxygenase 2, HER-2/neu, and P53 as Prognostic Factors in Endometrioid Endometrial Cancer

H. Boezen, H. Boezen, H. Hollema, 2009, International Journal of Gynecologic Cancer.